

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 March 2019 (07.03.2019)



(10) International Publication Number
WO 2019/046711 A2

(51) International Patent Classification:
A61K 31/4985 (2006.01) *C07D 487/04* (2006.01)

(21) International Application Number:
PCT/US2018/049081

(22) International Filing Date:
31 August 2018 (31.08.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/553,320 01 September 2017 (01.09.2017) US

(71) Applicants: **OPTIKIRA LLC** [US/US]; 20600 Chagrin Boulevard, Suite 210, Cleveland, Ohio 44122 (US). **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, 12 Floor, Oakland, California 94607 (US).

(72) Inventors: **KEENAN, Richard M.**; 471 School House Lane, Devon, Pennsylvania 19333 (US). **BACKES, Bradley J.**; 152 Liberty Street, San Francisco, California 94110 (US). **MALY, Dustin J.**; 7537 18th Avenue NW, Seattle, Washington 98117 (US). **REYNOLDS, Charles**; c/o BioMotiv, 20600 Chagrin Boulevard, Suite 210, Cleveland, Ohio 44122 (US). **WHITTAKER, Ben**; c/o BioMotiv, 20600 Chagrin Boulevard, Suite 210, Cleveland, Ohio 44122 (US). **KNIGHT, Jamie**; c/o BioMotiv, 20600 Chagrin Boulevard, Suite 210, Cleveland, Ohio 44122 (US). **SUTTON, Jon**; c/o BioMotiv, 20600 Chagrin Boulevard, Suite 210, Cleveland, Ohio 44122 (US). **HYND, George**; c/o BioMotiv, 20600 Chagrin Boulevard, Suite 210, Cleveland, Ohio 44122 (US). **PAPA, Feroz, R.**; c/o The Regents of the University of California, 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US). **OAKES, Scott, A.**; c/o The Regents of the University of California, 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US).

(74) Agent: **DOYLE, Kathryn** et al.; Saul Ewing Arnstein & Lehr LLP, Centre Square West, 1500 Market Street, 38th Floor, Philadelphia, Pennsylvania 19102 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WO 2019/046711 A2

(54) Title: COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION

(57) Abstract: The present invention provides novel compounds, compositions and methods for treating or preventing an IRE1 α -related disease or disorder. In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease, a demyelinating disease, cancer, an eye disease, a fibrotic disease, and diabetes.